MABFORGE
LIVE

Serial Number

98532731

Owner

Alloy Therapeutics, Inc.

Attorney

Ian J. Block

Filing Date

May 3, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MABFORGE Trademark

Serial Number: 98532731

MABFORGE is a trademark filed by Alloy Therapeutics, Inc. on May 3, 2024. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

Alloy Therapeutics, Inc. (6 trademarks)

275 Second Ave., Suite 200
Waltham, MA 02451

Entity Type: 03

Trademark Details

Filing Date

May 3, 2024

Registration Date

Not Registered

Published for Opposition

June 3, 2025

Goods & Services

Licensing of intellectual property to others in the fields of protein therapeutics, monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, and antibody derivatives

Research, development and consultation services in the fields of biotechnology, immunology, monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, antibody derivatives, vaccines, medicine, biotherapeutics, and therapeutics, namely, scientific research and development in the field of protein therapeutics, and conducting scientific research and development in the field of monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, and antibody derivatives for others; Genetic engineering services utilizing a collection of genetic technologies for the rapid production of human antibodies, human antibody fragments, and other proteins comprising such antibodies and fragments, namely, conducting genetic engineering for scientific research purposes for others, conducting testing, inspection, research, and development of protein therapeutic preparations for others; Scientific and medical research for use in antibody sequence humanization and optimization via deep mutational scanning (DMS); Conducting scientific medical and genetic research for others

Protein molecules for scientific, laboratory and medical research use; Diagnostic reagents for scientific or research use; Chemicals for use in biotherapeutics and therapeutics product development and manufacturing processes, namely, chemicals for use in biotechnological product development; Biochemicals, namely, polypeptide encoding nucleic acids for laboratory research use; Monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, and antibody derivatives for scientific and medical laboratory research use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 11, 2026 EXRA
TEAS STATEMENT OF USE RECEIVED
Feb 10, 2026 EISU
SOU EXTENSION 1 GRANTED
Feb 10, 2026 EX1G
SOU EXTENSION 1 FILED
Feb 10, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 10, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 7, 2025 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 5, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 5, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 5, 2025 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 3, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 3, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 28, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 30, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 28, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 28, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 28, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 27, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 27, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 27, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 18, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 30, 2024 NWOS
NEW APPLICATION ENTERED
May 3, 2024 NWAP